俄罗斯医药行业预测研究报告

俄罗斯医药行业2013年预测研究报告本文简介：窗体顶端俄罗斯医药行业2013年预测研究报告——RussianPharmaSectorForecastto2013联系购买电话：010-82863480公司名称：佐思信息公司地址：北京市海淀区苏州街18号院长远天地大厦A2座1008-1室（100080）2011.03摘要TheRussianphar

俄罗斯医药行业2013年预测研究报告本文内容：

窗体顶端

俄罗斯医药行业2013年预测研究报告——Russian

Pharma

Sector

Forecast

to

2013

联系购买电话：010-82863480

公司名称：佐思信息

公司地址：北京市海淀区苏州街18号院长远天地大厦A2座

1008-1室（100080）

2011.03

摘要

The

Russian

pharma

industry

is

one

of

the

most

prolific

sectors

in

the

healthcare

industry,showing

an

unprecedented

growth

of

over

17%

to

generate

revenue

worth

about

RUB

538

Billion

(US$

16.14

Billion)

in

2009.

This

high

growth

rate

can

be

attributed

to

the

development

incentives

announced

by

the

government

for

the

state

drugs

segment.

The

government

is

also

taking

the

required

steps

to

boost

the

domestic

pharma

industry

and

reduce

the

dependence

on

imported

products.

The

Para-pharmaceuticals

segment

has

become

one

of

the

leading

segments,which

has

been

benefited

from

the

strong

young

population

demand.

According

to

our

new

research

report

“Russian

Pharma

Sector

Forecast

to

2013”,the

Russian

pharma

sector

is

projected

to

show

double-digit

growth

in

near

future

owing

to

a

rise

in

investments

by

the

private

sector,most

importantly

the

foreign

players.

Besides,to

cater

to

a

large

percentage

of

the

population,pharma

companies

are

now

shifting

their

focus

towards

the

research

and

development

projects

for

manufacturing

generic

drugs

that

are

less

expensive.

To

understand

the

direction

of

the

industry,we

have

done

an

extensive

research

and

analysis

of

various

segments

of

the

pharma

market

in

the

Russian

Federation.

These

segments

include:

Commercial

Drug

Segment,State

Segment,and

the

Para-pharmaceutical

Segment.

Growth

of

the

Russian

pharmaceutical

industry

is

based

on

the

rising

health

conscious

and

consequent

rise

in

the

healthcare

expenditure

of

the

population.

Additionally,rising

prevalence

of

diseases

and

demand

for

cheaper

drugs

will

be

some

of

the

other

important

drivers

for

future

growth.

The

overall

improvement

in

the

healthcare

industry

will

also

pave

way

for

the

Russian

pharma

market

to

continue

its

upward

trend

during

the

forecast

period

(2011-2013).

The

report

provides

precise

and

reliable

information,supplemented

with

statistics,regarding

the

Russian

pharma

sector.

The

report

covers

leading

drugs,segment-wise

break

up,and

information

about

major

therapy

areas.

It

has

thoroughly

examined

current

market

trends;

industrial

developments,and

competitive

landscape

to

enable

clients

understand

the

market

structure

and

its

progress

in

coming

years.

Forecasts

have

been

done

considering

the

possible

impact

of

recession

on

the

industry.

The

report

also

presents

a

brief

overview

of

demographics

and

healthcare

profile

to

adjudge

the

pharmaceutical

market

in

terms

of

demands,expenditure,and

possible

future

direction.

目录

1.

Analyst

View

2.

Demographics

&

Healthcare

Profile

2.1

Life

Expectancy

2.2

Age

Breakup

2.3

Hospital

Beds

&

Doctors

2.4

Healthcare

Expenditure

3.

Pharmaceutical

Market

Forecast

to

2013

3.1

Market

Size

&

Growth

3.2

Comparative

Analysis

3.3

Market

Segmentation

by

Expenditure

3.4

Commercial

Drugs

Market

3.4.1

Imported

&

Domestic

Drugs

3.4.2

RX

&

OTC

Drugs

3.4.3

Sales

Structure

-

By

ATC

Groups

3.4.4

Leading

Companies

3.4.5

Leading

Drugs

3.4.6

Price

Analysis

3.5

State

Segment

3.5.1

Drug

Reimbursement

Program

(DLO)

3.5.1.1

Imported

&

Domestic

Drugs

3.5.1.2

RX

&

OTC

Drugs

3.5.1.3

Sales

Structure

-

By

ATC

Groups

3.5.1.4

Leading

Companies

3.5.1.5

Leading

Drugs

3.5.2

Hospital

Segment

3.5.2.1

Imported

&

Domestic

Drugs

3.5.2.2

Sales

Structure

-

By

ATC

Groups

3.5.2.3

Leading

Companies

3.5.2.4

Leading

Drugs

3.6

Parapharmaceutical

Market

3.6.1

Nutritional

Supplements

Market

3.6.1.1

Imported

&

Domestic

Supplements

3.7

Market

by

Disease

Segment

3.7.1

Cardiovascular

Drugs

3.7.2

Hepatitis

C

3.7.3

HIV

Drugs

3.7.4

High

Insulin

Demand

3.7.5

Cancer

Drugs

4.

Clinical

Trials

Market

Outlook

5.

Industry

Analysis

5.1

Market

Driving

Forces

5.1.1

Increasing

Volume

&

Sales

of

Expensive

Drugs

5.1.2

Rising

Expenditure

on

Infrastructure

Development

5.1.3

Increasing

Acceptance

of

the

Contract

Manufacturing

Model

5.1.4

Rising

Healthcare

Coverage

Improving

Drug

Affordability

5.2

Market

Roadblocks

5.2.1

Declining

Population

5.2.2

Drug

Counterfeiting

&

Weak

IPR

Regime

6.

Regulatory

Environment

7.

Competitive

Analysis

7.1

Sanofi-Aventis

7.2

Novartis

Pharma

ZAO

7.3

Roche

Moscow

Ltd.

7.4

Farmstandart

OAO

7.5

Akrikhin

OAO

List

of

Figures:

Figure

2-1:

Population

(Million),2007-2010

Figure

2-2:

Life

Expectancy

of

Male

&

Female

(Years),2005-2010

Figure

2-3:

Share

of

Young

&

Old

Age

Population

in

Total

Population

(2004-2010)

Figure

2-4:

Number

of

Doctors

(per

‘000

Population),2005-2010

Figure

2-5:

Share

of

Healthcare

Expenditure

in

GDP

(2007-2010)

Figure

2-6:

Per

Head

Healthcare

Expenditure

(US$),2007-2010

Figure

3-1:

Pharmaceutical

Market

(Billion

RUB),2007-2010

Figure

3-2:

Pharmaceutical

Market

Breakup

by

Segment

(%),2007-2010

Figure

3-3:

Forecast

for

Pharmaceutical

Market

(Billion

RUB),2011-2013

Figure

3-4:

Forecast

for

Pharmaceutical

Market

by

Segment

(%),2013

Figure

3-5:

Global

-

Top

Pharmaceutical

Retail

Markets

(Billion

US$),2009

Figure

3-6:

Global

-

Per

Head

Drug

Consumption

in

Top

Pharmaceutical

Markets

(US$),2009

Figure

3-7:

Share

of

Rx

&

OTC

Drugs

in

Out-of-Pocket

Expenditure

(2009)

Figure

3-8:

Share

of

Local

&

Imported

Drugs

in

Out-of-Pocket

Expenditure

(2009)

Figure

3-9:

Commercial

Drugs

Market

(Billion

RUB),2008-2010

Figure

3-10:

Forecast

for

Commercial

Drugs

Market

(Billion

RUB),2011-2013

Figure

3-11:

Share

of

Imported

&

Domestic

Drugs

in

Commercial

Drugs

Market

by

Sales

Value

(2007-2010)

Figure

3-12:

Share

of

Imported

&

Domestic

Drugs

in

Commercial

Drugs

Market

by

Sales

Volume

(2007-2010)

Figure

3-13:

Share

of

RX

&

OTC

Drugs

in

Commercial

Drugs

Market

by

Sales

Value

(2007-2010)

Figure

3-14:

Share

of

RX

&

OTC

Drugs

in

Commercial

Drugs

Market

by

Sales

Volume

(2007-2010)

Figure

3-15:

Growth

of

ATC

Groups

in

Commercial

Drugs

Market

(%),2009

Figure

3-16:

Price

Index

for

Drugs

in

Commercial

Drugs

Market

(%),2006-2009

Figure

3-17:

Price

Index

for

Imported

&

Domestic

Drugs

in

Commercial

Drugs

Market

(%),2006-2009

Figure

3-18:

Consumer

Price

Index

(%),2009

Figure

3-19:

State

Segment

of

Pharmaceutical

Market

(Billion

RUB),2007-2010

Figure

3-20:

Forecast

for

State

Segment

of

Pharmaceutical

Market

(Billion

RUB),2011-2013

Figure

3-21:

Disbursement

under

DLO

Program

(Billion

RUB),2008-2010

Figure

3-22:

Share

of

Imported

&

Domestic

Drugs

under

DLO

Program

by

Sales

Value

(2008-2010)

Figure

3-23:

Share

of

Imported

&

Domestic

Drugs

under

DLO

Program

by

Sales

Volume

(2008-2010)

Figure

3-24:

Share

of

RX

&

OTC

Drugs

under

DLO

Program

by

Sales

Value

(2008-2010)

Figure

3-25:

Share

of

RX

&

OTC

Drugs

under

DLO

Program

by

Sales

Volume

(2008-2010)

Figure

3-26:

Share

of

Imported

&

Domestic

Drugs

under

Hospital

Segment

by

Sales

Value

(2008-2010)

Figure

3-27:

Share

of

Imported

&

Domestic

Drugs

under

Hospital

Segment

by

Sales

Volume

(2008-2010)

Figure

3-28:

Parapharmaceutical

Market

(Billion

RUB),2008-2010

Figure

3-29:

Forecast

for

Parapharmaceutical

Market

(Billion

RUB),2011-2013

Figure

3-30:

Nutritional

Supplements

Market

(Million

US$),2008-2010

Figure

3-31:

Share

of

Imported

&

Domestic

Nutritional

Supplements

(2010)

Figure

3-32:

Deaths

by

Circulatory

System

Diseases

(Million),2002,2006

&

2010

Figure

3-33:

Hepatitis

C

Market

(Million

US$),2009-2013

Figure

3-34:

Number

of

HIV

Patients

(Million),2008-2010

Figure

3-35:

Number

of

Diagnosed

Diabetes

Patients

(Million),2010

&

2030

Figure

3-36:

Insulin

Market

(Million

US$),2007-2010

Figure

3-37:

Cancer

Deaths

(Per

100,000),2002,2006

&

2010

Figure

4-1:

Number

of

Clinical

Trials

Approved

(2007-2010)

Figure

4-2:

Number

of

Patients

Planned

to

be

recruited

in

Clinical

Trials

(2008-2010)

Figure

4-3:

Clinical

Trials

by

Therapeutic

Area

(%),2009

Figure

4-4:

Clinical

Trials

by

Sponsor

Country

(%),2009

Figure

5-1:

Commercial

Drug

Sales

by

Price

Category

(%),2008

&

2009

Figure

5-2:

Personal

Disposable

Income

(Billion

US$),2009-2013

Figure

5-3:

Forecast

for

Population

(Million),2011-2013

List

of

Tables:

Table

3-1:

Sales

Structure

of

ATC

Groups

in

Commercial

Drugs

Market

(2009)

Table

3-2:

Leading

Pharmaceutical

Companies

in

Commercial

Drugs

Market

by

Sales

(Million

RUB),2009

Table

3-3:

Leading

Drugs

in

Commercial

Drugs

Market

by

Sales

(Million

RUB),2009

Table

3-4:

Drugs

Sales

Structure

of

ATC

Groups

under

DLO

Program

(2009)

Table

3-5:

Leading

Pharmaceutical

Companies

under

DLO

Program

by

Sales

(Million

RUB),2009

Table

3-6:

Leading

Drugs

under

DLO

Program

by

Sales

(Million

RUB),2009

Table

3-7:

Sales

Structure

of

ATC

Groups

in

Hospital

Segment

(2009)

Table

3-8:

Leading

Pharmaceutical

Companies

by

Sales

under

Hospital

Segment

(Million

RUB),2009

Table

3-9:

Leading

Trade

Names

under

Hospital

Segment

by

Sales

(Million

RUB),2009

Table

4-1:

Number

of

Clinical

Trials

by

Top

Six

Sponsors

(2009)

Table

7-1:

Sanofi-Aventis

-

Strengths

&

Weaknesses

Table

7-2:

Novartis

Pharma

ZAO

-

Strengths

&

Weaknesses

Table

7-3:

Roche

Moscow

Ltd.

-

Strengths

&

Weaknesses

Table

7-4:

Farmstandart

OAO

-

Strengths

&

Weaknesses

Table

7-5:

Akrikhin

OAO

-

Strengths

&

Weaknesses

窗体底端